PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14636905-6 2003 Rosuvastatin also produced significantly greater reductions in apolipoprotein-B and all 4 major lipid ratios, as well as a significantly greater increases in apolipoprotein A-I (all p <0.001). Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 63-79 15024300-5 2004 All doses of rosuvastatin significantly reduced levels of atherogenic lipoprotein and apolipoproteins over placebo, including low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, apolipoprotein B and apolipoprotein C-III. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 266-307 11524058-9 2001 Significant, dose-dependent reductions in total cholesterol and apolipoprotein B with rosuvastatin were also observed (p <0.001). Rosuvastatin Calcium 86-98 apolipoprotein B Homo sapiens 64-80 12646336-5 2003 Significant differences favoring rosuvastatin 10 mg were also observed for total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, apolipoprotein (apo) B, and apo A-I versus atorvastatin 10 mg, and for total cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and apo B versus simvastatin 20 mg and pravastatin 20 mg. Rosuvastatin Calcium 33-45 apolipoprotein B Homo sapiens 159-181 12646336-5 2003 Significant differences favoring rosuvastatin 10 mg were also observed for total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, apolipoprotein (apo) B, and apo A-I versus atorvastatin 10 mg, and for total cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and apo B versus simvastatin 20 mg and pravastatin 20 mg. Rosuvastatin Calcium 33-45 apolipoprotein B Homo sapiens 306-311 12539816-11 2003 A recent double-blind, crossover study revealed that treatment with rosuvastatin resulted in marked reductions in apoB-containing lipoproteins in patients with type IIa or IIb dyslipidemia. Rosuvastatin Calcium 68-80 apolipoprotein B Homo sapiens 114-118 14644393-3 2003 Similar reductions on rosuvastatin were observed for both groups in LDL-C (NTG -60%; HTG -56%), apoB (both -49%), intermediate-density lipoprotein (NTG -57%; HTG -54%) and LDL circulating mass (NTG -52%, HTG -58%) (all P < 0.001 versus placebo), i.e., these changes were phenotype independent. Rosuvastatin Calcium 22-34 apolipoprotein B Homo sapiens 96-100 14644393-6 2003 Rosuvastatin therefore, in addition to lowering LDL and apoB-concentrations, largely corrected the TG and LDL abnormalities in subjects who had the propensity to develop the atherogenic lipoprotein phenotype. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 56-60 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 93-105 apolipoprotein B Homo sapiens 255-271 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 93-105 apolipoprotein B Homo sapiens 273-278 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 107-114 apolipoprotein B Homo sapiens 255-271 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 107-114 apolipoprotein B Homo sapiens 273-278 34657601-8 2021 LDL-C attainment rate is lower than apoB attainment rate with rosuvastatin therapy (P<0.05), which is mainly attributable to patients with low initial LDL-C. Rosuvastatin Calcium 62-74 apolipoprotein B Homo sapiens 36-40 32411300-14 2020 Conclusions: According to the NMAs, it can be concluded that rosuvastatin ranked 1st in LDL-C, ApoB-lowering efficacy and ApoA1-increasing efficacy. Rosuvastatin Calcium 61-73 apolipoprotein B Homo sapiens 95-99 31307833-11 2019 Total cholesterol levels, triglycerides, non-HDL-C, and apolipoprotein B were significantly reduced in the CND/RSV and RSV groups, with no significant differences between the groups compared with the CND group (P < 0.001 for all). Rosuvastatin Calcium 111-114 apolipoprotein B Homo sapiens 56-72 32065359-5 2020 RESULTS: After the 8-week treatment, percentage change (least-square means +- standard error) in the apoB/A1 ratio in the rosuvastatin/ezetimibe group was significantly decreased compared to the rosuvastatin group (- 46.14 +- 1.58% vs. - 41.30 +- 1.58%, respectively; P = 0.03). Rosuvastatin Calcium 122-134 apolipoprotein B Homo sapiens 101-105 32065359-7 2020 The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group. Rosuvastatin Calcium 83-95 apolipoprotein B Homo sapiens 58-62 32065359-7 2020 The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group. Rosuvastatin Calcium 124-136 apolipoprotein B Homo sapiens 58-62 32065359-9 2020 CONCLUSION: The apoB/A1 ratio was significantly reduced in patients receiving combination therapy with ezetimibe and rosuvastatin compared to those receiving rosuvastatin monotherapy. Rosuvastatin Calcium 117-129 apolipoprotein B Homo sapiens 16-20 32065359-9 2020 CONCLUSION: The apoB/A1 ratio was significantly reduced in patients receiving combination therapy with ezetimibe and rosuvastatin compared to those receiving rosuvastatin monotherapy. Rosuvastatin Calcium 158-170 apolipoprotein B Homo sapiens 16-20 30688048-6 2019 In addition, change in apoB/A1 ratio (-0.44+-0.16 in the rosuvastatin group and -0.47+-0.25 in the rosuvastatin/ezetimibe group, P=0.58) did not differ between the two groups. Rosuvastatin Calcium 57-69 apolipoprotein B Homo sapiens 23-27 30688048-6 2019 In addition, change in apoB/A1 ratio (-0.44+-0.16 in the rosuvastatin group and -0.47+-0.25 in the rosuvastatin/ezetimibe group, P=0.58) did not differ between the two groups. Rosuvastatin Calcium 99-111 apolipoprotein B Homo sapiens 23-27 30688048-9 2019 CONCLUSION: A 6-week combination therapy of low-dose rosuvastatin and ezetimibe showed LDL-C, apoB, and apoB/A1 ratio reduction comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus. Rosuvastatin Calcium 53-65 apolipoprotein B Homo sapiens 94-98 30688048-9 2019 CONCLUSION: A 6-week combination therapy of low-dose rosuvastatin and ezetimibe showed LDL-C, apoB, and apoB/A1 ratio reduction comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus. Rosuvastatin Calcium 53-65 apolipoprotein B Homo sapiens 104-108 31307833-11 2019 Total cholesterol levels, triglycerides, non-HDL-C, and apolipoprotein B were significantly reduced in the CND/RSV and RSV groups, with no significant differences between the groups compared with the CND group (P < 0.001 for all). Rosuvastatin Calcium 119-122 apolipoprotein B Homo sapiens 56-72 23600368-6 2013 Apolipoprotein B levels decreased by 15%, 7% and 4% in the rosuvastatin, add-on ER-NA/LRPT and add-on fenofibrate group, respectively (P < 0.01 for all compared with baseline, P < 0.01 for all comparisons between groups). Rosuvastatin Calcium 59-71 apolipoprotein B Homo sapiens 0-16 28392500-4 2017 Compared with placebo, rosuvastatin decreased LDL cholesterol and apoB-100 levels in TRL, lbLDL, and sdLDL by significantly increasing the fractional catabolic rate of apoB-100 (TRL, +45%; lbLDL, +131%; and sdLDL, +97%), without a change in production. Rosuvastatin Calcium 23-35 apolipoprotein B Homo sapiens 66-74 28392500-4 2017 Compared with placebo, rosuvastatin decreased LDL cholesterol and apoB-100 levels in TRL, lbLDL, and sdLDL by significantly increasing the fractional catabolic rate of apoB-100 (TRL, +45%; lbLDL, +131%; and sdLDL, +97%), without a change in production. Rosuvastatin Calcium 23-35 apolipoprotein B Homo sapiens 168-176 28392500-9 2017 Rosuvastatin enhances the catabolism of apoB-100 in both lbLDL and sdLDL. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 40-48 26087958-10 2015 Significant improvements in apoB were seen with both ezetimibe plus rosuvastatin (mean of -0.17 g/L, p < 0.001) and rosuvastatin 20 mg (mean of -0.13 g/L, p = 0.03) treatment groups, but did not differ between groups (p = 0.53). Rosuvastatin Calcium 68-80 apolipoprotein B Homo sapiens 28-32 26087958-10 2015 Significant improvements in apoB were seen with both ezetimibe plus rosuvastatin (mean of -0.17 g/L, p < 0.001) and rosuvastatin 20 mg (mean of -0.13 g/L, p = 0.03) treatment groups, but did not differ between groups (p = 0.53). Rosuvastatin Calcium 119-131 apolipoprotein B Homo sapiens 28-32 25816050-4 2015 Posttreatment changes with rosuvastatin (40 mg/d) in plasma ceramides were inversely associated with VLDL apoB-100 FCR (r = -0.62, P = .03) independent of changes in plasma triglycerides, cholesterol, and low-density lipoprotein-cholesterol. Rosuvastatin Calcium 27-39 apolipoprotein B Homo sapiens 106-114 25816050-7 2015 In the metabolic syndrome, the ability of rosuvastatin to increase VLDL apoB-100 FCR may reflect ceramide-specific mechanistic actions and/or sphingolipid exchange. Rosuvastatin Calcium 42-54 apolipoprotein B Homo sapiens 72-80 25809021-0 2015 Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 44-52 25809021-1 2015 Dose-associated effects of rosuvastatin on the metabolism of apolipoprotein (apo) B-100 in triacylglycerol rich lipoprotein (TRL, d < 1.019 g/ml) and low density lipoprotein (LDL) and of apoA-I in high density lipoprotein (HDL) were assessed in subjects with combined hyperlipidemia. Rosuvastatin Calcium 27-39 apolipoprotein B Homo sapiens 61-87 25809021-2 2015 Our primary hypothesis was that maximal dose rosuvastatin would decrease the apoB-100 production rate (PR), as well as increase apoB-100 fractional catabolic rate (FCR). Rosuvastatin Calcium 45-57 apolipoprotein B Homo sapiens 77-85 25809021-2 2015 Our primary hypothesis was that maximal dose rosuvastatin would decrease the apoB-100 production rate (PR), as well as increase apoB-100 fractional catabolic rate (FCR). Rosuvastatin Calcium 45-57 apolipoprotein B Homo sapiens 128-136 25809021-5 2015 Rosuvastatin at 5 and 40 mg/day decreased LDL cholesterol by 44 and 54% (both P < 0.0001), triacylglycerol by 14% (ns) and 35% (P < 0.01), apoB by 30 and 36% (both P < 0.0001), respectively, and had no significant effects on HDL cholesterol or apoA-I levels. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 145-149 25809021-7 2015 Rosuvastatin 5 and 40 mg/day increased TRL apoB-100 FCR by 36 and 46% (both ns) and LDL apoB-100 by 63 and 102% (both P < 0.05), respectively. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 43-51 25809021-7 2015 Rosuvastatin 5 and 40 mg/day increased TRL apoB-100 FCR by 36 and 46% (both ns) and LDL apoB-100 by 63 and 102% (both P < 0.05), respectively. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 88-96 25809021-10 2015 Our data indicate that maximal dose rosuvastatin treatment in subjects with combined hyperlipidemia resulted in significant increases in the catabolism of LDL apoB-100, with no significant effects on apoB-100 production or HDL apoA-I kinetics. Rosuvastatin Calcium 36-48 apolipoprotein B Homo sapiens 159-167 24230979-6 2014 For the percentage of changes in ApoB, a benefit was seen for rosuvastatin versus atorvastatin in the 1/1 (-6.06%) and 1/2 dose ratio (-1.80%). Rosuvastatin Calcium 62-74 apolipoprotein B Homo sapiens 33-37 24230979-10 2014 In conclusion, rosuvastatin might increase Apo A-I levels at all dose ratios and decrease ApoB levels and ApoB/A-I ratios in the 1/1 and 1/2 dose ratio versus atorvastatin. Rosuvastatin Calcium 15-27 apolipoprotein B Homo sapiens 90-94 24230979-10 2014 In conclusion, rosuvastatin might increase Apo A-I levels at all dose ratios and decrease ApoB levels and ApoB/A-I ratios in the 1/1 and 1/2 dose ratio versus atorvastatin. Rosuvastatin Calcium 15-27 apolipoprotein B Homo sapiens 106-110 21262787-7 2011 In addition to reducing serum cholesterol, the combined rosuvastatin/ezetimibe/Pcsk9 siRNA treatment exhibited a significant reduction in serum APOB protein and triglyceride levels. Rosuvastatin Calcium 56-68 apolipoprotein B Homo sapiens 144-148 23237107-3 2013 The present post hoc analysis from the Limiting UNdertreatment of lipids in Acute coronary syndrome with Rosuvastatin (LUNAR) study examined the relation of ApoB with LDL cholesterol and non-HDL cholesterol at baseline and during treatment with intensive statin therapy. Rosuvastatin Calcium 105-117 apolipoprotein B Homo sapiens 157-161 21867445-5 2011 RESULTS: Rosuvastatin resulted in statistically significant reductions of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and urate levels vs. placebo. Rosuvastatin Calcium 9-21 apolipoprotein B Homo sapiens 143-159 21867445-5 2011 RESULTS: Rosuvastatin resulted in statistically significant reductions of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and urate levels vs. placebo. Rosuvastatin Calcium 9-21 apolipoprotein B Homo sapiens 161-166 22204857-6 2013 RESULTS: When compared with pravastatin therapy, rosuvastatin therapy significantly reduced total, LDL cholesterol, and apolipoprotein B levels (P<0.05 by post-hoc comparison), but comparably improved flow-mediated dilation after 2 months. Rosuvastatin Calcium 49-61 apolipoprotein B Homo sapiens 120-136 23494963-15 2013 Following rosuvastatin 10 mg daily for 16 days, total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B were reduced from baseline by 30.6 %, 38.9 % and 30.6 %, respectively. Rosuvastatin Calcium 10-22 apolipoprotein B Homo sapiens 107-123 21859750-5 2011 Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). Rosuvastatin Calcium 75-87 apolipoprotein B Homo sapiens 203-219 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Rosuvastatin Calcium 62-74 apolipoprotein B Homo sapiens 110-126 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Rosuvastatin Calcium 53-65 apolipoprotein B Homo sapiens 108-113 21792295-43 2011 Of all agents available, rosuvastatin produces the greatest reduction in LDL-C, LDL-P, and improvement in apoA-I/apoB, together with a favorable safety profile. Rosuvastatin Calcium 25-37 apolipoprotein B Homo sapiens 113-117 20417447-2 2010 AIMS: To assess the efficacy of rosuvastatin 20mg versus atorvastatin 80 mg in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at 3 months. Rosuvastatin Calcium 32-44 apolipoprotein B Homo sapiens 129-133 20147603-4 2010 However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% +/- 14%, P = .04) and the combination group (-46% +/- 8%, P = .05) than in the atorvastatin group (-39% +/- 11%). Rosuvastatin Calcium 100-112 apolipoprotein B Homo sapiens 41-57 22101878-7 2011 RESULTS: The rosuvastatin administration resulted in significant reductions of total cholesterol, LDL cholesterol, and apolipoprotein B and a significant increase in HDL-C (from 1.43 mmol/l to 1.52 mmol/l, p=0.05), while the levels of apolipoprotein A1 remained unchanged. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 119-135 20417447-6 2010 Rosuvastatin 20mg was more effective than atorvastatin 80 mg in decreasing apoB/apoA-1 ratio at 1 month (-44.4% vs -42.9%, p=0.02) but not at 3 months (both -44.4%, p=0.87). Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 75-79 20417447-10 2010 CONCLUSION: In patients with non-ST-elevation acute coronary syndrome, rosuvastatin 20mg decreased apoB/apoA-1 ratio at 1 month more than atorvastatin 80 mg. No difference could be shown at 3 months; thus, the primary endpoint was not met. Rosuvastatin Calcium 71-83 apolipoprotein B Homo sapiens 99-103 20146674-11 2010 ApoB decreased more in ATO (-32.6%), than in ROS (-24%) group (p=0.049). Rosuvastatin Calcium 45-48 apolipoprotein B Homo sapiens 0-4 20524719-7 2010 Significant (p < or = 0.04 for all comparisons) improvements in non-HDL-C, ApoB, HDL-C, TG, and hsCRP levels were also observed with each of the rosuvastatin/fenofibric acid doses as compared with simvastatin 40 mg. Treatment-related AEs and discontinuations due to AEs were similar across groups. Rosuvastatin Calcium 148-160 apolipoprotein B Homo sapiens 78-82 19474729-4 2009 RECENT FINDINGS: Data from a series of recent studies, including Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin, Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy II, Treating to New Targets-Incremental Decrease in End Points Through Aggressive Lipid Lowering and Collaborative Atorvastatin Diabetes Study, demonstrating that apoB better identifies residual risk than non-HDL-C will be reviewed. Rosuvastatin Calcium 158-170 apolipoprotein B Homo sapiens 408-412 19900015-4 2009 Furthermore, rosuvastatin provides additional benefits in the lipid profile such as increased HDL-cholesterol, and decreased triglycerides, total cholesterol, apolipoprotein B and apolipoprotein B:A-1 ratio. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 159-175 19900015-4 2009 Furthermore, rosuvastatin provides additional benefits in the lipid profile such as increased HDL-cholesterol, and decreased triglycerides, total cholesterol, apolipoprotein B and apolipoprotein B:A-1 ratio. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 180-196 17367312-5 2007 Rosuvastatin also produced statistically significantly greater mean reductions from baseline in levels of total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B and lipid ratios. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 167-183 23555376-6 2009 The changes in HDL-C, ApoB, ApoA-1, and ApoB / ApoA-1 ratio showed significant improvement in the rosuvastatin group than in the atorvastatin group. Rosuvastatin Calcium 98-110 apolipoprotein B Homo sapiens 22-26 23555376-6 2009 The changes in HDL-C, ApoB, ApoA-1, and ApoB / ApoA-1 ratio showed significant improvement in the rosuvastatin group than in the atorvastatin group. Rosuvastatin Calcium 98-110 apolipoprotein B Homo sapiens 40-44 17416370-2 2008 Compared with placebo, there was a significant dose-dependent decrease with rosuvastatin in plasma cholesterol, triglycerides, LDL cholesterol, apoB and apoC-III concentrations and in the apoB/apoA-I ratio, lathosterol:cholesterol ratio, HDL cholesterol concentration and campesterol:cholesterol ratio also increased significantly. Rosuvastatin Calcium 76-88 apolipoprotein B Homo sapiens 144-148 17416370-3 2008 Rosuvastatin significantly increased the fractional catabolic rates (FCR) of very-low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and LDL-apoB and decreased the corresponding pool sizes, with evidence of a dose-related effect. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 161-165 17416370-4 2008 LDL apoB production rate (PR) fell significantly with rosuvastatin 40 mg/day with no change in VLDL and IDL-apoB PR. Rosuvastatin Calcium 54-66 apolipoprotein B Homo sapiens 4-8 17416370-6 2008 In the metabolic syndrome, rosuvastatin decreases the plasma concentration of apoB-containing lipoproteins by a dose-dependent mechanism that increases their rates of catabolism. Rosuvastatin Calcium 27-39 apolipoprotein B Homo sapiens 78-82 17416370-7 2008 Higher dose rosuvastatin may also decrease LDL apoB production. Rosuvastatin Calcium 12-24 apolipoprotein B Homo sapiens 47-51 19200542-0 2009 Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Rosuvastatin Calcium 38-50 apolipoprotein B Homo sapiens 64-83 19200542-5 2009 Both atorvastatin and rosuvastatin caused significant (p<0.0001) and similar median decreases in TG (-33.0%, -27.6%), RemL-C (-58.7%, -61.5%), and apoB-48 (-37.5%, -32.1%) as compared to baseline. Rosuvastatin Calcium 22-34 apolipoprotein B Homo sapiens 150-157 18535816-0 2008 Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. Rosuvastatin Calcium 17-29 apolipoprotein B Homo sapiens 62-66 18535816-8 2008 RESULTS: Rosuvastatin 20 mg significantly reduced plasma LDL-cholesterol, triacylglycerol and total ApoB. Rosuvastatin Calcium 9-21 apolipoprotein B Homo sapiens 100-104 18535816-11 2008 Rosuvastatin did not change the production rates of VLDL2-, IDL- or LDL-, but did reduce VLDL1-ApoB production rate (12.4 +/- 4.5 vs 19.5 +/- 8.4 mg kg(-1) day(-1), p = 0.035). Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 95-99 18691996-5 2008 Rosuvastatin 10 mg was dominant (ie, was more effective at a lower cost) relative to atorvastatin 10 and 20 mg, simvastatin 20 and 40 mg, and pravastatin 40 mg in terms of reductions in LDL-C, TC/ HDL-C ratio, TC, ApoB, and ApoB/ApoA-I ratio, increases in HDL-C, and attainment of the LDL-C goal. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 214-218 18691996-5 2008 Rosuvastatin 10 mg was dominant (ie, was more effective at a lower cost) relative to atorvastatin 10 and 20 mg, simvastatin 20 and 40 mg, and pravastatin 40 mg in terms of reductions in LDL-C, TC/ HDL-C ratio, TC, ApoB, and ApoB/ApoA-I ratio, increases in HDL-C, and attainment of the LDL-C goal. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 224-228 18809153-2 2008 AIM: The primary objective is to compare the efficacy of rosuvastatin 20 mg/day and atorvastatin 80 mg/day in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at three months, in ACS patients. Rosuvastatin Calcium 57-69 apolipoprotein B Homo sapiens 160-164 15910557-9 2005 A greater reduction in apoB/apoA1 was seen with RSV (-34.9%, -39.2% and -40.5%) than with ATV (-32.4%, -34.7% and -35.8%, P < 0.05 at weeks 12 and 18). Rosuvastatin Calcium 48-51 apolipoprotein B Homo sapiens 23-27 16950182-3 2006 Significantly greater decreases were also observed with rosuvastatin for total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein-B, and lipid ratios compared with milligram-equivalent doses of atorvastatin. Rosuvastatin Calcium 56-68 apolipoprotein B Homo sapiens 134-150 16644314-9 2006 Switching to rosuvastatin produced greater reductions in LDL-C, total cholesterol, non-HDL-C, apolipoprotein B, and lipid ratios. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 94-110 16307708-7 2005 Rosuvastatin also reduced LDL-C, total cholesterol/HDL-C significantly more than atorvastatin at all three time points, and significantly improved total cholesterol/HDL-C and apolipoprotein B/A-I ratios. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 153-191 16193198-3 2005 Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. Rosuvastatin Calcium 15-27 apolipoprotein B Homo sapiens 127-143 16144509-5 2005 Rosuvastatin, specifically, is a synthetic statin shown to lower low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol and triglycerides, in addition to increasing high-density lipoprotein cholesterol. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 121-137 15910557-14 2005 CONCLUSION: In subjects with type 2 diabetes, greater improvements of apoB/apoA1 and across the lipid profile were observed with RSV compared with ATV. Rosuvastatin Calcium 129-132 apolipoprotein B Homo sapiens 70-74 15823640-7 2005 Switching to rosuvastatin 10 mg from atorvastatin 20 mg produced significantly greater reductions in TC:HDL-C (P<0.025) and apo B:apo A-I (P<0.01). Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 127-132 15642550-4 2005 However, only rosuvastatin treatment significantly (p <0.05 to <0.001) reduced fasting low-density lipoprotein cholesterol, apolipoprotein B-100, apolipoprotein C-III, apolipoprotein C-III:B particles, the apolipoprotein B-100:apolipoprotein A-I ratio, and increased apolipoprotein A-I (p <0.05). Rosuvastatin Calcium 14-26 apolipoprotein B Homo sapiens 130-196 15642550-4 2005 However, only rosuvastatin treatment significantly (p <0.05 to <0.001) reduced fasting low-density lipoprotein cholesterol, apolipoprotein B-100, apolipoprotein C-III, apolipoprotein C-III:B particles, the apolipoprotein B-100:apolipoprotein A-I ratio, and increased apolipoprotein A-I (p <0.05). Rosuvastatin Calcium 14-26 apolipoprotein B Homo sapiens 130-150 15531001-7 2004 Over 6 weeks, rosuvastatin significantly reduced non-HDL-C, apo B, and all lipid and apolipoprotein ratios assessed, compared with milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin (all, P < 0.002). Rosuvastatin Calcium 14-26 apolipoprotein B Homo sapiens 60-65 15531001-9 2004 Rosuvastatin reduced apo B by 36.7% to 45.3% compared with 29.4% to 42.9% with atorvastatin, 22.2% to 34.7% with simvastatin, and 14.7% to 23.0% with pravastatin. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 21-26